Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Leukemia • Lymphoma • Internal Medicine • Hematology
How do you choose which BTK inhibitor to use in NHL?
Does the safety profile impact your choice significantly?
Does your first choice vary by disease histology?
Answer from: at Community Practice
At this point, I use very little ibrutinib. If I need CNS penetration, ibrutinib has a track record there. Otherwise, I have pivoted to acalabrutinib and zanubrutinib. I typically will pick by indication - acala for CLL and zanu for WM/MZL. In MCL or likely soon in CLL, I am not entirely sure how to...
Sign in or Register to read more